LivaNova (NASDAQ:LIVN) Price Target Cut to $60.00 by Analysts at Stifel Nicolaus

LivaNova (NASDAQ:LIVN) had its target price reduced by Stifel Nicolaus from $72.00 to $60.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 46.67% from the company’s current price.

LIVN has been the subject of a number of other reports. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Robert W. Baird boosted their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC decreased their price objective on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday. Mizuho cut their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Finally, Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $65.33.

LivaNova Trading Down 1.9 %

Shares of LIVN opened at $40.91 on Wednesday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.22 billion, a PE ratio of 97.26 and a beta of 1.00. LivaNova has a 1 year low of $40.51 and a 1 year high of $64.47. The stock has a 50 day simple moving average of $47.78 and a 200-day simple moving average of $49.62.

Insider Activity

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by insiders.

Institutional Investors Weigh In On LivaNova

A number of institutional investors and hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in LivaNova by 25.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 153,458 shares of the company’s stock valued at $7,107,000 after acquiring an additional 30,718 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of LivaNova by 74.3% in the 4th quarter. Squarepoint Ops LLC now owns 111,449 shares of the company’s stock valued at $5,161,000 after purchasing an additional 47,494 shares during the last quarter. Two Sigma Advisers LP grew its position in shares of LivaNova by 148.5% during the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock worth $9,936,000 after buying an additional 128,200 shares during the period. Two Sigma Investments LP raised its stake in shares of LivaNova by 27.2% during the fourth quarter. Two Sigma Investments LP now owns 439,582 shares of the company’s stock worth $20,357,000 after buying an additional 93,985 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new position in LivaNova in the fourth quarter valued at approximately $378,000. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.